Advent Life Sciences

[AviadoBio @AviadoBio]

We're pleased to announce that the first patient has been treated in the ASPIRE-FTD clinical trial, a first-in-human Phase 1/2 study of AVB-101 for people with #FrontotemporalDementia with GRN mutations. Learn more: https://t.co/QlkJbFIXex

#FTD #GeneTherapy #AviadoBio

[Advent Life Sciences @advent_ls]

https://t.co/UBxUHRd7Iv

[Advent Life Sciences @advent_ls]

https://t.co/MKPbVzgN0V

[Alessio Ciulli @alessiociulli]

Humble and touched to receive the #KEAwards2023 on behalf of @dundeeuni @AmphistaThera. This awards belongs to everyone at @UoDRIS @UoDLifeSciences @UoDCeTPD @advent_ls and many others who have contributed to the successful journey so far and commercial achievements of this Year

[AviadoBio @AviadoBio]

We are pleased to announce the initiation of ASPIRE-FTD, a Phase 1/2 study of AVB-101, a potentially transformative investigational #GeneTherapy for people with #FrontotemporalDementia (#FTD) with mutations in the progranulin (GRN) gene.

Learn more: https://t.co/98BhNKBjMo

[Advent Life Sciences @advent_ls]

https://t.co/enZIx7uDH5

[Amphista Therapeutics @AmphistaThera]

We are delighted to announce that we have achieved our first discovery milestone in the second active discovery programme in collaboration with @bmsnews. Read the full announcement here: https://t.co/IWtSlbsDSS #TPD #Biotech #Milestone

[Advent Life Sciences @advent_ls]

https://t.co/tYyALLzyOF

[Amphista Therapeutics @AmphistaThera]

We are delighted to announce that we have achieved our first discovery milestone in collaboration with @bmsnews. It’s another step towards delivering our mission to unlock the full potential of Targeted Protein Degradation. https://t.co/pJcg0eoMMu #TargetedProteinDegradation

[Cambridge University @Cambridge_Uni]

How do you turn early-stage science into high growth business? You produce university spin-outs: start-ups that take advantage of research breakthroughs.

Today, we – along with a group of leading universities and investors – have pooled our expertise to launch the USIT Guide.

[Aura Biosciences @AuraBiosciences]

At #TheMaculaSociety Annual Meeting, Dr. Ivana Kim presented positive interim data from our phase 2 trial of bel-sar for the treatment of early-stage #choroidal melanoma, via suprachoroidal administration. Full details on the data are in today’s release:
https://t.co/UMQhtofgNC

[Advent Life Sciences @advent_ls]

https://t.co/qURjkZFLcR

[Advent Life Sciences @advent_ls]

Portfolio progress at Advent founded Pheno Therapeutics:

https://t.co/egwy0i4HkL

[Advent Life Sciences @advent_ls]

Progress in our Portfolio:

https://t.co/zqgx11NuNx

[Advent Life Sciences @advent_ls]

https://t.co/63Fo8bO3BY

[Aura Biosciences @AuraBiosciences]

We are excited to announce our $80.4M financing! This funding will support our pipeline and global phase 3 trial evaluating bel-sar as the potential first approved therapy for the treatment of
early-stage #choroidalmelanoma
$AURA
https://t.co/705D76Hylk

[Advent Life Sciences @advent_ls]

https://t.co/gmrEq7lS8z

[Advent Life Sciences @advent_ls]

https://t.co/8JdCFV0hXD

[Life Science Integrates @LSIntegrates]

Join us in Oct to hear Freddie discuss VC investment in the session ‘VC judges: what is the X factor?’ with Nathan Sigworth, PharmaCCX, Eric Halioua, @pdc_line, Oliver Sexton, @UKI2S, Dominic Schmidt, @advent_ls, Chris Baker, @lifearc1 & Karolina Zapadka, @ParkwalkAdvisor

[Advent Life Sciences @advent_ls]

We are proud to announce that our portfolio company PIC Therapeutics has raised a $35m Series A to advance into the clinic.

#oncology #VentureCapital
https://t.co/FFzn9ik8yo